Study of REM-422 in Patients With AML or Higher Risk MDS

The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML

Trial Details

NCT ID
NCT06297941
Phase
PHASE1
Sponsor
Remix Therapeutics
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • REM-422
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Tampa, Florida, United States|27.94752,-82.45843
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • New York, New York, United States|40.71427,-74.00597
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Be able to provide informed consent.
  • Be 18 or older at the time of informed consent.
  • Disease criteria:
  • Histologically confirmed diagnosis of either:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →